Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305093 | 0.83 | GABRA1 (0.43) | HMGCRGABRA1GABRB2KDM4EGAA | |
| Hydrochloric Acid SCHEMBL31414207 | 0.80 | POLB (0.44) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL12257695 | 0.74 | POLB (0.39) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL26182160 | 0.73 | HMGCR (0.37) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL23920002 | 0.73 | HRH4 (0.40) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL23919952 | 0.73 | KDM4E (0.44) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL17403518 | 0.73 | GABRA1 (0.46) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL19154841 | 0.73 | HMGCR (0.37) | HMGCRGABRA1GABRB2KDM4EGAA | |
| SCHEMBL23920273 | 0.72 | HMGCR (0.32) | HMGCRKDM4EHSD17B10 | |
| SCHEMBL25619247 | 0.70 | HMGCR (0.36) | HMGCRGABRA1GABRB2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | HMGCR 3875/4885GABRA1 3186/4885GABRB2 2818/4885 |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | IL4, IL2, IL4I1 | HMGCR 3875/4885GABRA1 3186/4885GABRB2 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.